A review based on a quick and heavily compromised cost-effectiveness evaluation conducted in secret with a threat to delist unless the company accepted a significant price reduction. Apparently, this is what constitutes a pricing negotiation in 2019. …
Latest Video
New Stories
-
COVID-19 vaccine manufacturing, supply and administration programs
January 22, 2021 - - Latest News -
Bionomics-BMS combination completes trial treatment phase
January 22, 2021 - - Australian Biotech -
Almac Group survey reveals pandemic impact on clinical trial activity
January 22, 2021 - -
Industry slams last minute Trump move to cut medicine coverage
January 22, 2021 - -
Queensland research institute in new cell therapy trial
January 21, 2021 - - Latest News -
This is what being 'among the first in the world' looks like
January 21, 2021 - - Latest News -
Hundreds of exemptions from active ingredient prescribing
January 21, 2021 - - Latest News